Experiences of serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT)
Background: This study aims to provide evidence of factors that impact participant reported serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT). Methods: Data from an 18-month longitudinal retrospective cohort of individuals receiving iOAT wa...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Journal of Affective Disorders Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666915323002329 |
| _version_ | 1797355243753701376 |
|---|---|
| author | Tianna Magel Ying C MacNab Scott MacDonald Eugenia Oviedo-Joekes |
| author_facet | Tianna Magel Ying C MacNab Scott MacDonald Eugenia Oviedo-Joekes |
| author_sort | Tianna Magel |
| collection | DOAJ |
| description | Background: This study aims to provide evidence of factors that impact participant reported serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT). Methods: Data from an 18-month longitudinal retrospective cohort of individuals receiving iOAT was utilized. The outcomes of serious depression and serious anxiety were ascertained via self-report in the European Addiction Severity Index. Two Generalized Linear Mixed Models were formulated using Penalized Quasi-Likelihood method. Results: Analyses included 131 participants. Average age was 49.04 years, 31 % self-identified as female, and 30 % self-identified as Indigenous. Adjusted analysis identified the importance of poorer physical health (AOR:1.06; 95 % CI: 1.03, 1.08), illicit opioid use (AOR: 1.03; 95 %CI: 1.01, 1.06), emotional abuse (AOR: 2.01; 95 % CI: 1.17, 3.44), and social isolation (AOR: 1.95; 95 % CI: 1.06, 3.58) with serious depression. Adjusted analysis of serious anxiety identified associations with age (AOR: 0.95; 95 % CI: 0.92, 0.98), illicit benzodiazepine use (AOR:1.31 95 % CI: 1.06, 1.61), poorer physical health (AOR: 1.05; 95 % CI: 1.03, 1.07), and social problems (AOR: 2.09; 95 % CI: 1.18, 3.71). Limitations: Generalizability of study findings may be limited given the criteria used to enroll participants and to define depression and anxiety. Conclusion: Depression and anxiety are highly prevalent among clients receiving iOAT. While both disorders share several factors, there are distinct characteristics associated with each outcome. These include poorer physical health, experiences of abuse, illicit substance use, and social problems. Understanding factors that influence depression and anxiety in iOAT can assist providers in supporting iOAT clients' mental health and developing individualized care plans. |
| first_indexed | 2024-03-08T14:08:26Z |
| format | Article |
| id | doaj.art-d2ccf04b92ec488b8cbb381da16d60be |
| institution | Directory Open Access Journal |
| issn | 2666-9153 |
| language | English |
| last_indexed | 2024-03-08T14:08:26Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Affective Disorders Reports |
| spelling | doaj.art-d2ccf04b92ec488b8cbb381da16d60be2024-01-15T04:24:18ZengElsevierJournal of Affective Disorders Reports2666-91532024-01-0115100695Experiences of serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT)Tianna Magel0Ying C MacNab1Scott MacDonald2Eugenia Oviedo-Joekes3School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada; Corresponding author.School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, CanadaProvidence Health Care, Providence Crosstown Clinic, 77 E Hastings St, Vancouver, BC V6A 2R7, CanadaSchool of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada; Centre for Advancing Health Outcomes, Providence Health Care, St. Paul's Hospital, 575-1081 Burrard St., Vancouver, BC V6Z 1Y6, CanadaBackground: This study aims to provide evidence of factors that impact participant reported serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT). Methods: Data from an 18-month longitudinal retrospective cohort of individuals receiving iOAT was utilized. The outcomes of serious depression and serious anxiety were ascertained via self-report in the European Addiction Severity Index. Two Generalized Linear Mixed Models were formulated using Penalized Quasi-Likelihood method. Results: Analyses included 131 participants. Average age was 49.04 years, 31 % self-identified as female, and 30 % self-identified as Indigenous. Adjusted analysis identified the importance of poorer physical health (AOR:1.06; 95 % CI: 1.03, 1.08), illicit opioid use (AOR: 1.03; 95 %CI: 1.01, 1.06), emotional abuse (AOR: 2.01; 95 % CI: 1.17, 3.44), and social isolation (AOR: 1.95; 95 % CI: 1.06, 3.58) with serious depression. Adjusted analysis of serious anxiety identified associations with age (AOR: 0.95; 95 % CI: 0.92, 0.98), illicit benzodiazepine use (AOR:1.31 95 % CI: 1.06, 1.61), poorer physical health (AOR: 1.05; 95 % CI: 1.03, 1.07), and social problems (AOR: 2.09; 95 % CI: 1.18, 3.71). Limitations: Generalizability of study findings may be limited given the criteria used to enroll participants and to define depression and anxiety. Conclusion: Depression and anxiety are highly prevalent among clients receiving iOAT. While both disorders share several factors, there are distinct characteristics associated with each outcome. These include poorer physical health, experiences of abuse, illicit substance use, and social problems. Understanding factors that influence depression and anxiety in iOAT can assist providers in supporting iOAT clients' mental health and developing individualized care plans.http://www.sciencedirect.com/science/article/pii/S2666915323002329DepressionAnxietyInjectable opioid agonist treatmentOpioid use disorderPerson-centered care |
| spellingShingle | Tianna Magel Ying C MacNab Scott MacDonald Eugenia Oviedo-Joekes Experiences of serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT) Journal of Affective Disorders Reports Depression Anxiety Injectable opioid agonist treatment Opioid use disorder Person-centered care |
| title | Experiences of serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT) |
| title_full | Experiences of serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT) |
| title_fullStr | Experiences of serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT) |
| title_full_unstemmed | Experiences of serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT) |
| title_short | Experiences of serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT) |
| title_sort | experiences of serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment ioat |
| topic | Depression Anxiety Injectable opioid agonist treatment Opioid use disorder Person-centered care |
| url | http://www.sciencedirect.com/science/article/pii/S2666915323002329 |
| work_keys_str_mv | AT tiannamagel experiencesofseriousdepressionandseriousanxietyamongindividualsreceivinginjectableopioidagonisttreatmentioat AT yingcmacnab experiencesofseriousdepressionandseriousanxietyamongindividualsreceivinginjectableopioidagonisttreatmentioat AT scottmacdonald experiencesofseriousdepressionandseriousanxietyamongindividualsreceivinginjectableopioidagonisttreatmentioat AT eugeniaoviedojoekes experiencesofseriousdepressionandseriousanxietyamongindividualsreceivinginjectableopioidagonisttreatmentioat |